Chirality-Guided Optimization of A 2A Adenosine Receptor Antagonists for Enhanced Metabolic Stability and Antitumor Efficacy
Journal of Medicinal Chemistry · 24.07.2025 · 68 (14) · 14962-14980
DOI: 10.1021/acs.jmedchem.5c01141 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 27.06.2025. Verfasst von Wen Ding und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Anti-Infective Drug Discovery and Development, Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery, Sch…. Hauptthemen laut MEDLINE: Adenosine A2 Receptor Antagonists, Receptor, Adenosine A2A, Antineoplastic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Special Project for Research and Development in Key areas of Guangdong Province, Basic and Applied Basic Research Foundation of Guangdong Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Blockade of the A2A adenosine receptor (A2AAR) by small-molecule antagonists holds promise for enhancing the efficacy of immune checkpoint inhibitors such as PD-L1 antibodies. However, many A2AAR antagonists suffer from limited clinical success due to poor metabolic stability. In this study, we introduce chirality into the A2AAR antagonist scaffold to address this challenge. This approach led to the discovery of (S)-E8, a chiral compound with markedly improved binding affinity, cellular activity, and in vivo potency compared with AZD4635, a Phase II clinical candidate. In contrast, its enantiomer (R)-E8 displays rapid metabolism and low efficacy, highlighting the importance of stereochemistry for therapeutic performance. Mechanistic studies identified CYP1A2 as the primary enzyme driving the metabolic differences among the enantiomers. These findings underscore the value of chirality-guided design in optimizing drug-like properties and reveal CYP1A2's pivotal role in enantioselective metabolism, offering a promising direction for the development of next-generation A2AAR antagonists.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Anti-Infective Drug Discovery and Development, Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 5100…
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou 510060, China.
- Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
- Guangdong Basic Research Center of Excellence for Functional Molecular Engineering, Sun Yat-Sen University, Guangzhou 510006, China.
- Division of Abdominal Tumor Multimodality Treatment and Laboratory of Cell Engineering and Immunotherapy, Cancer Center and State Key Laboratory of Biotherapy and Frontiers Science Center for Disease-related Molecular N…
ORCID-Profile: Xiaolei Zhang, Taoda Shi, Wenhao Hu
Förderung
- Special Project for Research and Development in Key areas of Guangdong Province
- Basic and Applied Basic Research Foundation of Guangdong Province
- National Natural Science Foundation of China
- Research and Development Program of Guangzhou National Laboratory
Zitieren
APA
Ding, W., Liu, S., Liu, W., Zhang, Z., Zhao, J., Zhang, X., Shi, T., & Hu, W. (2025). Chirality-Guided Optimization of A 2A Adenosine Receptor Antagonists for Enhanced Metabolic Stability and Antitumor Efficacy. Journal of Medicinal Chemistry, 68(14), 14962-14980. https://doi.org/10.1021/acs.jmedchem.5c01141
Vancouver
Ding W, Liu S, Liu W, Zhang Z, Zhao J, Zhang X, et al. Chirality-Guided Optimization of A 2A Adenosine Receptor Antagonists for Enhanced Metabolic Stability and Antitumor Efficacy. Journal of Medicinal Chemistry. 2025;68(14):14962-14980. doi:10.1021/acs.jmedchem.5c01141
BibTeX
@article{Ding2025,
author = {Ding, Wen and Liu, Shuhao and Liu, Wenjiang and Zhang, Zhijing and Zhao, Jingyu and Zhang, Xiaolei and Shi, Taoda and Hu, Wenhao},
title = {Chirality-Guided Optimization of A 2A Adenosine Receptor Antagonists for Enhanced Metabolic Stability and Antitumor Efficacy},
journal = {Journal of Medicinal Chemistry},
year = {2025},
volume = {68},
number = {14},
pages = {14962--14980},
doi = {10.1021/acs.jmedchem.5c01141}
}
EUVIMED